10x Genomics, Inc. Stock

10xgenomics.comHealthcare / BioTech & PharmaFounded: 2012Funding to Date: $222.59MM

10x Genomics is a biotechnology company offering a range of products including software and hardware all aimed at better understanding biological systems.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to 10x Genomics, Inc. before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

10x Genomics, Inc. Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

10x Genomics, Inc. Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
01/07/2019 Series D-1 $35MM $xx.xx $1.34B Fidelity, Meritech Capital, Wells Fargo
Price per Share
$xx.xx
Shares Outstanding
2,749,411
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Fidelity, Meritech Capital, Wells Fargo
04/26/2018 Series D $50MM $xx.xx $1.31B Fidelity International, Meritech Capital Partners, Paladin Capital Group, Phoenix International Investments, Softbank Capital, Wells Fargo
Price per Share
$xx.xx
Shares Outstanding
5,224,660
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Fidelity International, Meritech Capital Partners, Paladin Capital Group, Phoenix International Investments, Softbank Capital, Wells Fargo
03/17/2016 Series C $55MM $xx.xx $400.05MM Fidelity Management & Research Company, Foresite Capital Management, Js Capital Management, Paladin Capital Group, Softbank Capital, Venrock
Price per Share
$xx.xx
Shares Outstanding
12,281,720
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Fidelity Management & Research Company, Foresite Capital Management, Js Capital Management, Paladin Capital Group, Softbank Capital, Venrock
01/12/2015 Series B $55.5MM $xx.xx $222MM Foresite Capital Management, Morgan Stanley Alternative Investment Partners, Paladin Capital Group, Venrock, Vital Venture Capital
Price per Share
$xx.xx
Shares Outstanding
16,972,477
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Foresite Capital Management, Morgan Stanley Alternative Investment Partners, Paladin Capital Group, Venrock, Vital Venture Capital
10/30/2013 Series A-2 $22.4MM $xx.xx $56.05MM Foresite Capital Management, Paladin Capital Group
Price per Share
$xx.xx
Shares Outstanding
20,486,543
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Foresite Capital Management, Paladin Capital Group
10/17/2012 Series A-1 $4.69MM $xx.xx $2.78MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
5,523,394
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

Leadership & Board

Leadership

Serge Saxonov
Chief Executive Officer, Co-founder
Brad Crutchfield
Chief Commercial Officer
Ben Hindson
Chief Scientific Officer, President, Co-founder
Justin McAnear
Chief Financial Officer
Jean Philibert
Chief People Officer
Sam Ropp
Senior Vice President, Global Sales
Jonathan Schimmel
Vice President, Global Support and Sales Operations
Michael Schnall-Levin
Senior Vice President, R&D, Founding Scientist
Alexander Wong
Senior Vice President, Product, Software & Infrastructure
Paul Wyatt
Vice President, Operations
Eric Whitaker
General Counsel

Board

Serge Saxonov
Shehnaaz Suliman, M.D., M.Phil., M.B.A.
Sri Kosaraju
Penumbra
Mathai Mammen
Janssen
Bryan Roberts, Ph.D.
Venrock
John Stuelpnagel
Ben Hindson

10x Genomics, Inc. stock FAQs

plusminus

Can you buy 10x Genomics, Inc. stock?

You can no longer buy 10x Genomics, Inc. stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy 10x Genomics, Inc. stock?

You can no longer buy 10x Genomics, Inc. stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell 10x Genomics, Inc. stock?

You can no longer sell stock of 10x Genomics, Inc. on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell 10x Genomics, Inc. stock?

You can no longer sell stock of 10x Genomics, Inc. on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is 10x Genomics, Inc. a public company?

10x Genomics, Inc. is now a public company traded on NASDAQ with ticker TXG.
plusminus

What is 10x Genomics, Inc.’s stock price?

The stock price of 10x Genomics, Inc. is $42.01 as of 1/18/24.
plusminus

What is 10x Genomics, Inc.’s stock ticker symbol?

The ticker symbol of 10x Genomics, Inc. is TXG.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

10x Genomics, Inc. News and Media Highlights

10x Genomics Prices Initial Public Offering | FinSMEs

10x Genomics, a Pleasonton, Calif.-based company that build products combining hardware, chemistry, and software to give single cell and spatial views of biological systems, priced its initial public offering
Browse Insights
Updated on: Dec 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.